Dear All, Three things today… First, there is a newly announced hearing by the House Energy and Commerce at 9AM on this Friday, 28 April entitled “Antimicrobial Resistance: Examining an Emerging Public Health Threat.” Go here for details including a link for a livestream of hearing. It’s exciting to see this coming up … hopefully, it
Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018! Dear All, In
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Exciting and intriguing news to share about PASTEUR (and see this 16 June 2021 newsletter if you need a refresher on the ideas behind PASTEUR)! A new draft is now circulating with the intent of attaching it to a larger bill that is on track
Dear All, The US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) has announced it is looking for new members! As a reminder, PACCARB was founded in 2014 and is the advisory body for the US National Action Plan for Combating Antimicrobial Bacteria. The first National Action Plan ran from 2015 to 2020 and the second
Dear All, The WHO has announced a call for expressions of interests from AMR survivors and their caregivers to serve in the inaugural WHO Task Force of AMR Survivors! WHO are specifically looking for both (i) survivors of a drug-resistant infection and (ii) anyone who was a direct caregiver of such a patient. Their goal is
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All, On 6 Jan 2022, we had the announcement of the creation of in France of the ARPEGE consortium (AppRoche théraPeutique Economique & diaGnostique de l’antibiorésistancE) or “Economic, diagnostic and therapeutic approach to antibiotic resistance.” Somebody definitely had fun with that acronym! Here’s what you need to know: The French government is providing €9m of
Dear All (and with thanks to ATMF’s Damiano de Felice for co-authoring this newsletter), Last week, the team at ATMF (Access to Medicine Foundation) released a 3rd update to the AMR Benchmark series that they started in 2018. For those not familiar with the ATMF, its independent analyses (all its funding is from governments or private
https://www.youtube.com/watch?v=f0-xt3FrAGU&ab_channel=AMR.SolutionswithDr.JohnRex Dear All, VERY exciting news on the Pull incentive front: The G7 Finance Ministers have released a statement on Actions to Support Antibiotic Development, aiming to strengthen G7 preparedness against the “silent pandemic” of antimicrobial resistance. Implicitly, this is a statement that is agreed and endorsed by the political leadership of each country —
Dear All, Our US government colleagues have been busy! Three things back-to-back: First, the FORWARD Act (Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2022”) was introduced in the US Senate on 13 Jan 2021 as S.3498 by Sens. Kelly, Sinema, and Feinstein. You’ve got to admire the acronymics! The Senate bill is the
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust